tbuckley/cabot-search huggingface dataset:
Effect of alanine onD-galactosamine-induced acute liver failure in rats
Authors: K Maezono, K Mawatari, K Kajiwara, A Shinkai, T Maki
Journal: Hepatology (1996)

The effect of high–dose alanine on survival and liver function in rats with acute liver failure caused by a lethal dose of d–galactosamine (d–gal) was studied. Greater than 90% of control animals died within 5 days after d–gal injection, but alanine significantly decreased mortality, even when treatment was started at 12 hours after d–gal injection. Alanyl–glutamine had a slight effect, but glucose produced no improvement. There was marked elevation of the plasma aspartate transaminase (AST) level, prolongation of the prothrombin time, and a decrease of the arterial ketone body ratio (AKBR) and hepatic adenosine triphosphate (ATP) content within 12 hours after d–gal injection. The AKBR decreased in parallel with the decrease of the hepatic ATP content. These parameters were significantly improved in alanine– treated rats at 48 hours after the induction of liver damage, which was just before control rats began to die. The hepatic ATP content was significantly greater in alanine–treated rats than in the other rats (including normal controls), but glucose pretreatment had no effect. It was also found that the liver labeling index of partially hepatectomized rats was significantly elevated by alanine administration at 3 hours before measurement. In conclusion, alanine is effective for the treatment of experimental acute liver failure, probably caused by promotion of ATP synthesis. Ala may be a good candidate for clinical application because of its preventive effect on hepatocyte necrosis and its promotive effect on liver regeneration.
Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia
Authors: Henrik Lilljebjörn, Christina Orsmark-Pietras, Felix Mitelman, Anna Hagström-Andersson, Thoas Fioretos
Journal: Seminars in Cancer Biology (2021)

Transcriptional profiling of acute leukemia, specifically by RNA-sequencing or whole transcriptome sequencing (WTS), has provided fundamental insights into its underlying disease biology and allows unbiased detection of oncogenic gene fusions, as well as of gene expression signatures that can be used for improved disease classification. While used as a research tool for many years, RNA-sequencing is becoming increasingly used in clinical diagnostics. Here, we highlight key transcriptomic studies of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) that have improved our biological understanding of these heterogeneous malignant disorders and have paved the way for translation into clinical diagnostics. Recent single-cell transcriptomic studies of ALL and AML, which provide new insights into the cellular ecosystem of acute leukemia and point to future clinical utility, are also reviewed. Finally, we discuss current challenges that need to be overcome for a more wide-spread adoption of RNA-sequencing in clinical diagnostics and how this technology significantly can aid the identification of genetic alterations in current guidelines and of newly emerging disease entities, some of which are critical to identify because of the availability of targeted therapies, thereby paving the way for improved precision medicine of acute leukemia.
503P Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR)
Authors: M. Benavides, J. Alcaide-Garcia, E. Torres, S. Gil, G. Durán, C. Reyna, R. Wolman, M. Alvarez, M. Kushnir, I. Faull, M. Muñoz, E. Alba
Journal: Annals of Oncology (2021)
543P Neoadjuvant MRx0518 treatment is associated with significant gene and metagene signature changes in solid tumours
Authors: M. Lythgoe, M. Adriani, J. Stebbing, J. Clark, E. Pickford, A. Frampton, D. Liu, M. Kyrgiou, E. Rees, G. Fyvie, A. Stevenson, J. Krell
Journal: Annals of Oncology (2021)
166P Hereditary breast, ovarian and pancreatic cancers: Looking beyond the BRCA1/2 genes
Authors: M. Bono, D. Fanale, L. Incorvaia, N. Barraco, C. Brando, V. Calò, D. Cancelliere, L.R. Corsini, A. Dimino, C. Filorizzo, A. Fiorino, V. Gristina, L. Magrin, E. Pedone, A. Perez, A. Pivetti, R. Scalia, R. Sciacchitano, V. Bazan, A. Russo
Journal: Annals of Oncology (2021)
1726P The optimal care study: Outcomes of patients with solid malignancies admitted to intensive care unit
Authors: J.C. Laguna Montes, M. Garcia De Herreros, J. Padrosa, T.D. Barreto Zambrano, C. Zamora, M. Viladot, L. Fernandez-Mañas, T. Gorria, L. Ghiglione, E. Segui Solis, M. Chicote, C. Barrera, E. Font, S. Fernandez-Mendez, A. Téllez, P. Castro, J.M. Nicolas, A. Tuca, A. Prat, J. Marco-Hernández
Journal: Annals of Oncology (2021)
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Authors: Daolin Tang, Guido Kroemer, Rui Kang
Journal: Molecular Cancer (2021)

Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS, NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis and cancer progression. The targeting of RAS with drugs is challenging because RAS lacks classic and tractable drug binding sites. Over the past 30 years, this perception has led to the pursuit of indirect routes for targeting RAS expression, processing, upstream regulators, or downstream effectors. After the discovery that the KRAS-G12C variant contains a druggable pocket below the switch-II loop region, it has become possible to design irreversible covalent inhibitors for the variant with improved potency, selectivity and bioavailability. Two such inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), were recently evaluated in phase I-III trials for the treatment of non-small cell lung cancer with KRAS-G12C mutations, heralding a new era of precision oncology. In this review, we outline the mutations and functions of KRAS in human tumors and then analyze indirect and direct approaches to shut down the oncogenic KRAS network. Specifically, we discuss the mechanistic principles, clinical features, and strategies for overcoming primary or secondary resistance to KRAS-G12C blockade.
1237P Gut microbiome profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
Authors: W. Saifon, N. Trachu, A. Charoenyingwattana, S. Oranratnachai, C.R. Runcharoen, N. Monnamo, W. Sukasem, P. Inchareon, P.C. Chansriwong, T. Ativitavas, R. Panvichian, W. Chantratita, T. Reungwetwattana
Journal: Annals of Oncology (2021)
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
Authors: Hajime Nagasu, Yuichiro Yano, Hiroshi Kanegae, Hiddo J.L. Heerspink, Masaomi Nangaku, Yosuke Hirakawa, Yuka Sugawara, Naoki Nakagawa, Yuji Tani, Jun Wada, Hitoshi Sugiyama, Kazuhiko Tsuruya, Toshiaki Nakano, Shoichi Maruyama, Takashi Wada, Kunihiro Yamagata, Ichiei Narita, Kouichi Tamura, Motoko Yanagita, Yoshio Terada, Takashi Shigematsu, Tadashi Sofue, Takafumi Ito, Hirokazu Okada, Naoki Nakashima, Hiromi Kataoka, Kazuhiko Ohe, Mihoko Okada, Seiji Itano, Akira Nishiyama, Eiichiro Kanda, Kohjiro Ueki, Naoki Kashihara
Journal: Diabetes Care (2021)

Randomized controlled trials have shown kidney-protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown.Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease.At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL/min per 1.73 m2, and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL/min/1.73 m2 per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26-0.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (Pheterogeneity ≥ 0.35).The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.
1069P Granulomatous and sarcoid-like immune adverse events following CTLA4 and PD1 blockade adjuvant therapy of high-risk melanoma: A combined analysis of ECOG-ACRIN E1609 and SWOG S1404 phase III trials
Authors: A. Noor, I. Yassine, S.J. Lee, M. Othus, J. Moon, J.M. Kirkwood, V. Sondak, A. Ribas, K.F. Grossmann, A.A. Tarhini
Journal: Annals of Oncology (2021)
1725P Outcomes of cancer patients after ICU admission: Beyond mortality data
Authors: M. Garcia De Herreros, J.C. Laguna Montes, J. Padrosa, T.D. Barreto Zambrano, C. Zamora, M. Viladot, T. Gorria, L. Fernandez-Mañas, L. Ghiglione, E. Segui Solis, I. Casablancas, A. Marin, A. Pascual, S. Fernandez-Mendez, A. Téllez, P. Castro, J.M. Nicolas, A. Tuca, A. Prat, J. Marco-Hernández
Journal: Annals of Oncology (2021)
1659P Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer
Authors: N. Yan, S.X. Guo, M.J. Li, S.Y. Huang, Q.Q. Guo, D. Geng, H.X. Zhang, X. Li
Journal: Annals of Oncology (2021)
Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study
Authors: Sara Khan, Palma Solano-Paez, Tannu Suwal, Mei Lu, Salma Al-Karmi, Ben Ho, Iqra Mumal, Mary Shago, Lindsey M Hoffman, Andrew Dodgshun, Sumihito Nobusawa, Uri Tabori, Ute Bartels, David S Ziegler, Jordan R Hansford, Vijay Ramaswamy, Cynthia Hawkins, Christelle Dufour, Nicolas André, Eric Bouffet, Annie Huang, Almeida Gonzalez CV, Derek Stephens, Sarah Leary, Paula Marrano, Adriana Fonseca, Nirav Thacker, Bryan K. Li, Holly B. Lindsay, Alvaro Lassaletta, Anne E. Bendel, Christopher Moertel, Andres Morales La Madrid, Vicente Santa-Maria, Cinzia Lavarino, Eloy Rivas, Sebastian Perreault, Benjamin Ellezam, Alexander G Weil, Nada Jabado, Angelica Oviedo, Michal Yalon-Oren, Laura Amariglio, Helen Toledano, Rina Dvir, James Loukides, Timothy E. Van Meter, Hideo Nakamura, Tai-Tong Wong, Kuo-Sheng Wu, Chien-Jui Cheng, Young-Shin Ra, Milena La Spina, Luca Massimi, Anna Maria Buccoliero, Alyssa Reddy, Rong Li, G. Yancey Gillespie, Dariusz Adamek, Jason Fangusaro, David Scharnhorst, Joseph Torkildson, Donna Johnston, Jean Michaud, Lucie LafayCousin, Jennifer Chan, Frank Van Landeghem, Beverly Wilson, Sandra Camelo-Piragua, Nabil Kabbara, Mahjouba Boutarbouch, Derek Hanson, Chad Jacobsen, Karen Wright, Rajeev Vibhakar, Jean M. Levy, Yin Wang, Daniel Catchpoole, Nicholas Gerber, Michael A. Grotzer, Violet Shen, Ashley Plant, Christopher Dunham, Maria Joao Gil da Costa, Ramya Ramanujachar, Eric Raabe, Jeffery Rubens, Joanna Phillips, Nalin Gupta, Haci Ahmet Demir, Christine Dahl, Mette Jorgensen, Eugene I. Hwang, Roger J Packer, Amy Smith, Enrica Tan, Sharon Low, Jian-Qiang Lu, Ho- Keung Ng, Jesse L. Kresak, Sridharan Gururangan, Scott L. Pomeroy, Nongnuch Sirachainan, Suradej Hongeng, Vanan Magimairajan, Roona Sinha, Naureen Mushtaq, Reuben Antony, Mariko Sato, David Samuel, Michal Zapotocky, Samina Afzal, Andrew Walter, Tarik Tihan, Derek S. Tsang, Amar Gajjar, Paul Wood, Jason E. Cain, Peter A. Downie, Nicolas Gottardo, Helen Branson, Suzanne Laughlin, Birgit Ertl-Wagner, Abhaya V. Kulkarni, Michael D. Taylor, James Drake, George M. Ibrahim, Peter B. Dirks, James T. Rutka, Gino R. Somers, Lili-Naz Hazrati, Franck Bourdeaut, Laetitia Padovani, Richard G. Grundy, Claire M. Mazewski, Maryam Fouladi
Journal: The Lancet Child & Adolescent Health (2021)
1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Authors: S.J. Klempner, C. Sirard, J. Chao, V. Chiu, D. Mahalingam, H. Uronis, M. Kagey, J. Baum, F. Dayyani, J. Song, J. Wang, S. Iqbal, M. Tejani, M.B. Sonbol, A.J. Scott, Z. Wainberg, J.A. Ajani
Journal: Annals of Oncology (2021)
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial
Authors: Ivan O. Rosas, George Diaz, Robert L. Gottlieb, Suzana M. Lobo, Philip Robinson, Bradley D. Hunter, Adilson W. Cavalcante, J. Scott Overcash, Nicola A. Hanania, Alan Skarbnik, Julia Garcia-Diaz, Ivan Gordeev, Jordi Carratalà, Oliver Gordon, Emily Graham, Nicholas Lewin-Koh, Larry Tsai, Katie Tuckwell, Huyen Cao, Diana Brainard, Julie K. Olsson
Journal: Intensive Care Medicine (2021)

Trials of tocilizumab in patients with severe COVID-19 pneumonia have demonstrated mixed results, and the role of tocilizumab in combination with other treatments is uncertain. Here we evaluated whether tocilizumab plus remdesivir provides greater benefit than remdesivir alone in patients with severe COVID-19 pneumonia. This randomized, double-blind, placebo-controlled, multicenter trial included patients hospitalized with severe COVID-19 pneumonia requiring > 6 L/min supplemental oxygen. Patients were randomly assigned (2:1 ratio) to receive tocilizumab 8 mg/kg or placebo intravenously plus ≤ 10 days of remdesivir. The primary outcome was time from randomization to hospital discharge or "ready for discharge" (defined as category 1, assessed by the investigator on a 7-category ordinal scale of clinical status) to day 28. Patients were followed for 60 days. Among 649 enrolled patients, 434 were randomly assigned to tocilizumab plus remdesivir and 215 to placebo plus remdesivir. 566 patients (88.2%) received corticosteroids during the trial to day 28. Median time from randomization to hospital discharge or "ready for discharge" was 14 (95% CI 12–15) days with tocilizumab plus remdesivir and 14 (95% CI 11–16) days with placebo plus remdesivir [log-rank P = 0.74; Cox proportional hazards ratio 0.97 (95% CI 0.78–1.19)]. Serious adverse events occurred in 128 (29.8%) tocilizumab plus remdesivir and 72 (33.8%) placebo plus remdesivir patients; 78 (18.2%) and 42 (19.7%) patients, respectively, died by day 28. Tocilizumab plus remdesivir did not shorten time to hospital discharge or "ready for discharge" to day 28 compared with placebo plus remdesivir in patients with severe COVID-19 pneumonia.
Siglec-9は血管接着タンパク質1に対する新奇な白血球リガンドであり,炎症や癌のPETイメージングに使用できる
Authors: Aalto Kristiina, Autio Anu, A Kiss Elina, Elima Kati, Nymalm Yvonne, Z Veres Tibor, Marttila-Ichihara Fumiko, Elovaara Heli, Saanijoki Tiina, R Crocker Paul, Maksimow Mikael, Bligt Eva, A Salminen Tiina, Salmi Marko, Roivainen Anne, Jalkanen Sirpa
Journal: Blood (2011)
Time to reconsider what Global Burden of Disease studies really tell us about low back pain
Authors: Chris Maher, Giovanni Ferreira
Journal: Annals of the Rheumatic Diseases (2021)

Most of us have read publications where the introduction includes a statistic from one of the Global Burden of Disease (GBD) studies.1 2 We may be told that musculoskeletal conditions are very common,3 low back pain (LBP) is the leading cause of disability worldwide,4 neck pain is most prevalent in Scandinavia3 and the burden of osteoarthritis is increasing,5 but have you ever stopped to think about the data underpinning these claims?

In this perspective, we considered three limitations of the GBD Study that need to be borne in mind when considering GBD Study results. We used LBP as an exemplar, but the limitations apply more generally. But first we begin with an introduction to the metrics used in the GBD Study.

### GBD 101

There are four GBD Study metrics commonly used to provide information on the societal impact of LBP: incidence, prevalence, years lived with disability (YLDs) and disability adjusted life years (DALYs). Incidence reflects the number of new cases of LBP. Prevalence describes the proportion of the population experiencing LBP and is important as it drives the final two metrics. YLD estimates the amount of healthy life that is lost due to poor health, where 1 YLD represents the equivalent of 1 full year of healthy life lost. DALYs combine years of life lost (YLL) due to poor health (YLD) and YLL due to premature mortality. One DALY represents 1 year of healthy life lost because of poor health or premature mortality.

The GBD Study estimates loss of healthy life with disability weights proportional to the severity of ill health. For LBP, there are six health states representing increasingly severe LBP (table 1). Severity distributions are used to describe the proportion of the population with LBP experiencing each of these six health states.

View this table:

Table 1 
Low back pain (LBP) …
Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
Authors: Karama Asleh, Dongsheng Tu, Dongxia Gao, Vivien Bramwell, Mark N. Levine, Kathleen I. Pritchard, Lois E. Shepherd, Torsten O. Nielsen
Journal: Clinical Cancer Research (2021)

Accurate IHC biomarkers incorporating nestin positivity or inositol polyphosphate-4-phosphate (INPP4B) loss have recently been optimized to identify the basal-like intrinsic breast cancer subtype regardless of estrogen, progesterone, or Her2 status. We examined the predictive capacity of these basal biomarkers in the CCTG MA.5 chemotherapy and MA.12 endocrine therapy trials.Formalin-fixed paraffin embedded blocks of primary tumors from patients randomized in the two trials were used to build tissue microarrays. IHC staining for nestin and INPP4B followed published methods and REMARK criteria. A prespecified statistical plan tested the hypothesis that patients with basal breast cancer (nestin+ or INPP4B-) would not benefit from anthracycline substitution in MA.5 or from tamoxifen in MA.12.Nestin positivity or INPP4B loss was observed in 110/453 (24%) interpretable samples from MA.5 and 47/366 (13%) from MA.12, and was associated with high grade, younger age, estrogen receptor negativity, triple-negative, core basal, and PAM50 basal-like subtypes. In the MA.5 trial, patients assigned as basal experienced lower benefit from anthracycline versus nonanthracycline adjuvant chemotherapy [HR, 1.49; 95% confidence interval (CI), 0.72-3.10] when compared with non-basal (nestin- and INPP4B+) cases where there was a higher benefit from anthracyclines (HR, 0.75; 95% CI, 0.54-1.04; Pinteraction = 0.01). In the MA.12 trial, patients assigned as basal did not demonstrate a benefit from adjuvant tamoxifen versus placebo (HR, 0.48; 95% CI, 0.12-1.86; P = 0.29), whereas nonbasal cases displayed significant benefit (HR, 0.66; 95% CI, 0.45-0.98; P = 0.04), although the interaction test was not significant.The nestin/INPP4B IHC panel identifies women with basal breast cancers who benefit from nonanthracycline chemotherapy but not endocrine adjuvant treatments.
1770P Genomic correlates of clinical outcomes in patients with metastatic uveal melanoma (mUM) treated with tebentafusp (tebe)
Authors: L. de la Cruz Merino, Z. Eroglu, L. Collins, A. Greenshields-Watson, S. Stanhope, S. Abdullah, K. Ranade, J. Sacco
Journal: Annals of Oncology (2021)
1009P Current strategies of cell and gene therapy for solid tumors: Preliminary results of the joint international ESMO and EBMT Cell Therapy and Immunobiology Working Party questionnaire-based survey
Authors: P. Comoli, G. Pentheroudakis, P. Pedrazzoli, A. Ruggeri, U. Koehl, F. Lordick, K. Mauff, J.D. Hoogenboom, A. Urbano-Ispizua, S. Peters, C. Chabannon, J.B.A.G. Haanen
Journal: Annals of Oncology (2021)
LBA31 High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)
Authors: J. Van Dorp, B.B.M. Suelmann, N. Mehra, M. Van Montfoort, N. Van Dijk, K. Hendricksen, J. de Feijter, T. Boellaard, A. Daletzakis, C.U. Blank, R. Meijer, T. van der Heijden, B.W.G. van Rhijn, M.S. van der Heijden
Journal: Annals of Oncology (2021)
Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older
Authors: Anthony Simone, John Herald, Aiyu Chen, Neil Gulati, Albert Yuh-Jer Shen, Bruno Lewin, Ming-Sum Lee
Journal: JAMA Internal Medicine (2021)

Limor Friedensohn, MD; Dan Levin, MD; Maggie Fadlon-Derai, MHA; Liron Gershovitz, MD; Noam Fink, MD; Elon Glassberg, MD; Barak Gordon, MD
Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer
Authors: Ke-Ren Zhang, Yu-Fei Zhang, Hui-Min Lei, Ya-Bin Tang, Chun-Shuang Ma, Qian-Ming Lv, Shi-Yi Wang, Li-Ming Lu, Ying Shen, Hong-Zhuan Chen, Liang Zhu
Journal: Science Translational Medicine (2021)

AKR1B1 boosts glutathione de novo synthesis as a metabolic mechanism driving resistance to EGFR-targeted therapy in mouse models of lung cancer.
Marine Omega-3 Fatty Acids as Predictors of Morbidity in Patients with Coronary Artery Disease: Cross-Sectional Study in an Urban Area
Authors: Tani Shigemasa, Nagao Ken, Anazawa Takeo, Kawamata Hirofumi, Furuya Shingo, Takahashi Hiroshi, Iida Kiyoshi, Matsumoto Michiaki, Washio Takehiko, Kumabe Narimichi, Onikura Motoyuki, Hirayama Atsushi
Journal: Circulation (2011)
831MO Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
Authors: Y-K. Shi, J. Cui, H. Zhou, X. Zhang, L.Q. Zou, H. Liu, H. Zhang, X. Li, W. Zhang, F. Zhou, L. Zhong, C. Jin, H. Zhang, Z. Peng, Y. Gao, J. Cao, T. Ma
Journal: Annals of Oncology (2021)
1761MO Defining subset-wise myeloid responses to immune checkpoint blockade in melanoma
Authors: R. Cooper, I. Nassiri, R.A. Watson, C.A. Taylor, O. Tong, P. Kumar Sharma, A. Verge de los Aires, E.A. Mahé, S. Danielli, B.P. Fairfax
Journal: Annals of Oncology (2021)
635P Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer
Authors: H-M. Lin, B. Mak, K. Huynh, E.M. Kwan, H. Fettke, B. Tran, I.D. Davis, K.L. Mahon, M.R. Stockler, K. Briscoe, G.M. Marx, P. Du, J. Yu, S. Jia, A.M. Joshua, A.A. Azad, L.M. Butler, P.J. Meikle, L.G. Horvath
Journal: Annals of Oncology (2021)
Author Correction: Genetics of 35 blood and urine biomarkers in the UK Biobank
Authors: Nasa Sinnott-Armstrong, Yosuke Tanigawa, David Amar, Nina Mars, Christian Benner, Matthew Aguirre, Guhan Ram Venkataraman, Michael Wainberg, Hanna M. Ollila, Tuomo Kiiskinen, Aki S. Havulinna, James P. Pirruccello, Junyang Qian, Anna Shcherbina, Fatima Rodriguez, Themistocles L. Assimes, Vineeta Agarwala, Robert Tibshirani, Trevor Hastie, Samuli Ripatti, Jonathan K. Pritchard, Mark J. Daly, Manuel A. Rivas
Journal: Nature Genetics (2021)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Authors: Sara Y Tartof, Jeff M Slezak, Heidi Fischer, Vennis Hong, Bradley K Ackerson, Omesh N Ranasinghe, Timothy B Frankland, Oluwaseye A Ogun, Joann M Zamparo, Sharon Gray, Srinivas R Valluri, Kaije Pan, Frederick J Angulo, Luis Jodar, John M McLaughlin
Journal: The Lancet (2021)